Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
126
-
Total 13F shares, excl. options
-
63.1M
-
Shares change
-
+3.1M
-
Total reported value, excl. options
-
$243M
-
Value change
-
+$12.2M
-
Put/Call ratio
-
0.34
-
Number of buys
-
62
-
Number of sells
-
-66
-
Price
-
$3.85
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q1 2020
151 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2020.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.1M shares
of 123M outstanding shares and own 51.24% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.47M shares), STATE STREET CORP (7.44M shares), ARMISTICE CAPITAL, LLC (5.4M shares), VANGUARD GROUP INC (5.14M shares), MANGROVE PARTNERS (4.36M shares), GOLDMAN SACHS GROUP INC (1.96M shares), GEODE CAPITAL MANAGEMENT, LLC (1.54M shares), PURA VIDA INVESTMENTS, LLC (1.45M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (1.33M shares), and NORTHERN TRUST CORP (1.23M shares).
This table shows the top 126 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.